OM-85-IN / Optimus Holding - LARVOL DELTA

Safety and Tolerability of Intranasal OM-85 (OM-85-IN) in Healthy Volunteers and Patients With Mild Allergic Asthma: A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study (ATS 2025) - "These findings indicate that the direct application of OM-85-IN to the nasal mucosa is safe and well tolerated. Upcoming Phase 1b in patients with mild asthma will study safety and tolerability in diseased conditions including potential protection from nasal allergen challenge."

Clinical • P1 data • Asthma • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Respiratory Diseases

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: OM Pharma SA | Active, not recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients (clinicaltrials.gov) - P1 | N=41 | Active, not recruiting | Sponsor: OM Pharma SA | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study Investigating OM-85-IN Safety and Tolerability in Healthy Volunteers and Mild Allergic Asthma Patients (clinicaltrials.gov) - P1 | N=41 | Recruiting | Sponsor: OM Pharma SA

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases